Comparison of one-year clinical outcomes between intravascular ultrasound-guided versus angiography-guided implantation of drug-eluting stents for left main lesions: A single-center analysis of a 1,016-patient cohort by Gao, X.-F. (Xiao-Fei) et al.
© 2014 Gao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Patient Preference and Adherence 2014:8 1299–1309
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1299
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S65768
comparison of one-year clinical outcomes 
between intravascular ultrasound-guided versus 
angiography-guided implantation of drug-eluting 
stents for left main lesions: a single-center analysis 
of a 1,016-patient cohort
Xiao-Fei gao1,*
Jing Kan1,*
Yao-Jun Zhang1,2
Jun-Jie Zhang1
nai-liang Tian1
Fei Ye1
Zhen ge1
Ping-Xi Xiao1
Feng chen3
gary Mintz4
shao-liang chen1
1Department of cardiology, nanjing 
First hospital, nanjing Medical 
University, nanjing, People’s republic 
of china; 2Thorax center, erasmus 
Medical center, rotterdam, the 
netherlands; 3Department of 
epidemiology and Biostatistics, 
school of Public health, nanjing 
Medical University, nanjing, People’s 
republic of china; 4Division of 
cardiology, cardiovascular research 
Foundation, columbia University, 
new York, nY, UsA
*These authors contributed equally 
contributed to this work
Background: The importance of intravascular ultrasound (IVUS)-guided stenting of the 
unprotected left main coronary artery (ULMCA) remains controversial and has not been fully 
studied in the subset of patients with ULMCA. This study evaluated the clinical outcome of 
IVUS-guided stenting using a drug-eluting stent for ULMCA. 
Methods: A total of 1,016 consecutive patients with ULMCA stenosis who underwent drug-
eluting stent implantation from January 2006 to December 2011 were prospectively registered. 
The primary endpoint of this nonrandomized registry was the rate of one-year major adverse 
cardiac events (MACE, including cardiac death, myocardial infarction, and target vessel revas-
cularization). Stent thrombosis served as the safety endpoint. Propensity score matching was 
used to calculate the adjusted event rate. 
Results: The unadjusted one-year MACE rate was 14.8% in the IVUS-guided group (n=337, 
33.2%), significantly different from the 27.7% (P0.001) in the angiography-guided group 
(n=679, 66.8%). After propensity score matching, 291 paired patients were matched between 
the two groups, and the difference in one-year MACE between IVUS-guided (16.2%) versus 
angiography-guided (24.4%) groups was still significant (P=0.014), mainly driven by decreased 
rates of cardiac death (1.7%) and target vessel revascularization (3.4%) in the IVUS-guided group 
when compared with 5.2% (P=0.023) and 10.0% (P=0.002) in the angiography-guided group, 
respectively. Although it did not reach significance (P=0.075), the adjusted one-year rate of stent 
thrombosis in the angiography-guided group was higher than in the IVUS-guided group.
Conclusion: Compared with angiography guidance, IVUS-guided treatment of ULMCA 
using a drug-eluting stent was associated with a significant reduction of one-year cardiac death 
and target vessel revascularization, resulting in less frequent one-year MACE after propensity 
score matching.
Keywords: unprotected left main, intravascular ultrasound, major adverse cardiac events
Introduction
In the modern drug-eluting stent (DES) era, percutaneous coronary intervention of 
unprotected left main coronary artery (ULMCA) stenosis has been increasing rapidly.1 
Percutaneous coronary intervention remains a class IIa2 or IIb3 recommendation in 
current practice guidelines because of its higher rates of target vessel revasculariza-
tion (TVR) in distal ULMCA bifurcation lesions.4,5 Intravascular ultrasound (IVUS) 
overcomes many of the limitations of angiography by providing more accurate 
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quantitative information about vessel size, lesion length, and 
lesion sites.6–8 Previous studies have reported a reduction 
of unadjusted rates of cardiac death, myocardial infarction, 
stent thrombosis, and instent restenosis after placement of a 
DES in the left main artery when guided by IVUS.9,10 This 
reduction was consistently noted in a recent meta-analysis 
by Zhang et al11 when overall coronary artery lesions were 
included. Nonetheless, there is still a lack of definitive data 
regarding the importance of IVUS-guided DES implantation 
for a diseased left main vessel.12 Accordingly, this prospec-
tive registry is designed to address the clinical benefits of 
IVUS-guided stenting of ULMCA stenosis. 
Materials and methods
study design and patient population
From January 2006 to December 2011, a total of 1,016 con-
secutive real-world patients with ULMCA lesions (defined 
as diameter stenosis 50% by visual estimation) treated with 
DES implantation at our center were prospectively enrolled 
into this nonrandomized, open-label, single-center registry. 
Six of the experienced primary operators involved in this 
research routinely performed IVUS. For the purposes of this 
study, IVUS was performed at the discretion of the operators 
who agreed on the definitions of optimal angiographic and 
IVUS criteria. However, IVUS was also required if the opera-
tor needed to know the reference vessel diameter, expanding 
status of stent struts, instent haziness, strut fracture, or edge 
dissection. Patients included in the study were divided into an 
IVUS-guided group and a conventional angiography-guided 
group. The procedure was considered IVUS-guided when opti-
mal stent implantation was achieved after IVUS assessment or 
post-dilation was performed after suboptimal stent placement. 
Patients were included in the angiography-guided group if 
they had stent implantation by angiography or IVUS defined 
suboptimal stent placement without further post-dilation (failed 
to achieve optimal stent implantation successfully or not 
thought to influence clinical outcomes based on the operator’s 
decision). The clinical outcomes and independent outcome 
predictors between these two groups were compared. 
Both interventionists and surgeons agreed on the treat-
ments of percutaneous coronary intervention. The study was 
approved by the ethics committee and written informed consent 
was obtained from all patients prior to inclusion in the study. 
Procedures and periprocedural 
medications
All interventional procedures were performed in accordance 
with current standards. Use of glycoprotein IIb/IIIa inhibitors, 
low molecular weight heparin, type of DES, predilation, and 
intra-aortic balloon pump were at the operator’s discretion. 
A 300 mg loading dose of clopidogrel was administered 
before the index procedure. Post-dilation using a noncompli-
ant balloon (1.0:1.0 ratio of balloon/stent) was recommended 
in both groups and upsized as necessary in patients with 
suboptimal expansion or stent malapposition, as shown by 
angiography or IVUS. IVUS was performed only if patients 
were not at risk of circulatory collapse. Post-procedural IVUS 
was recommended to further evaluate the quality of stenting 
and was left to the operator’s discretion. IVUS images were 
obtained using a commercially available imaging system with 
a 40 MHz mechanical transducer (Boston Scientific Corpora-
tion, Natick, MA, USA). IVUS-defined optimal results were 
TIMI (Thrombolysis In Myocardial Infarction) flow grade 3, 
minimum stent lumen cross-sectional area 6.9 mm2, full 
apposition of stent, and no major dissection.10,13 Angio-
graphic success was defined as TIMI grade 3 and residual 
stenosis 10%. After the intervention, all patients received 
aspirin 100 mg/day for life and clopidogrel 75 mg/day for 
at least 12 months.
Study endpoints and definitions
The primary endpoint was the one-year rate of major adverse 
cardiac events (MACE), defined as cardiac death, myocardial 
infarction, and TVR. The safety endpoint was the occurrence 
of stent thrombosis. All deaths were considered cardiac in 
origin unless a noncardiac cause was confirmed clinically or 
at autopsy. Myocardial infarction was diagnosed in accordance 
with Third Universal Definition of Myocardial Infarction.14 
Target lesion revascularization and TVR were defined as 
repeat revascularization (including percutaneous coronary 
intervention and coronary artery bypass grafting) for target 
lesions and target vessels, respectively, in the presence of 
symptoms or objective signs of ischemia. Stent thrombosis 
was then classified by the Academic Research Consortium 
definition as definite, probable, or possible, and as early 
(0–30 days post stent implantation), late (31–360 days), or 
very late (360 days).15 The definition of definite stent throm-
bosis describes symptoms suggestive of an acute coronary syn-
drome and angiographic or pathological confirmation of stent 
thrombosis. Probable stent thrombosis included unexplained 
death within 30 days or target vessel myocardial infarction 
without angiographic confirmation of stent thrombosis. Pos-
sible stent thrombosis included any unexplained death after 30 
days. Lesion specificities were defined according to American 
Heart Association/American College of Cardiology criteria.16 
The New Risk Stratification (NERS) and Synergy between 
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Percutaneous Coronary Intervention with Taxus and Cardiac 
Surgery scores (SYNTAX) were prognostication before stent-
ing of unprotected left main stenosis.17,18
clinical follow-up
Clinical follow-up was performed either by telephone or 
through a clinical office visit. Telephone interviews were 
conducted at 1, 6, 9, and 12 months. Repeat coronary angiog-
raphy was scheduled at 12 months after the index procedure, 
or earlier if clinically indicated. An independent committee 
that was blinded to the study assessed all clinical events. 
statistical analysis
The Kolmogorov–Smirnov test was used to assess the dis-
tribution of continuous variables. Continuous variables were 
expressed as the mean ± standard deviation or median and 
were compared using the Student’s t-test (for normal data) 
and Mann–Whitney U-test (for non-normally distributed vari-
ables) as appropriate. Categorical variables were presented 
as frequencies or percentages and compared using chi-square 
statistics or Fisher’s Exact test. Survival curves were gener-
ated by the Kaplan–Meier method and compared using the 
log-rank test. A propensity score analysis was performed to 
minimize any selection bias due to differences in baseline 
characteristics between the two treatment groups.19 Vari-
ables included in the logistic regression model to calculate 
the propensity score were age, sex, hypertension, diabetes, 
hyperlipidemia, smoking history, serum creatinine, unstable 
angina, acute myocardial infarction, chronic renal insuf-
ficiency, peripheral arterial disease, left ventricular ejection 
fraction, previous bypass surgery, previous percutaneous 
intervention, multivessel disease, use of glycoprotein IIb/IIIa 
receptor inhibitors, lesion location, lesion tortuosity, calcifica-
tion or thrombus, restenotic lesion, chronic total occlusion, a 
transfemoral or transradial approach, and incomplete revas-
cularization. Model discrimination was assessed with the 
C-statistic and model calibration with the Hosmer–Lemeshow 
test. The new propensity score was then incorporated into 
Cox proportional hazards regression models as a covariate 
to assess the efficacy of IVUS guidance versus angiography 
guidance. In addition, to reduce the effect of treatment selec-
tion bias and potential confounding in this observational 
study, we performed rigorous adjustment for significant 
differences in the baseline characteristics of patients with 
propensity score matching using the following algorithm: 1:1 
optimal match with a ±0.03 caliper and no replacement. Mul-
tivariable Cox proportional hazards regression modeling was 
performed to determine independent predictors of the primary 
endpoint with purposeful selection of covariates. Variables 
associated at univariate analysis (all with a P-value 0.1) 
and those judged to be of clinical importance from previously 
published reports were eligible for inclusion into the multi-
variable model-building process. The goodness of fit of the 
Cox multivariable model was assessed with the Grønnesby–
Borgan–May test. The results are reported as hazard ratios 
with associated 95% confidence intervals and P-values. All 
statistical analyses were performed with Stata version 12.0 
(Stata Corporation, College Station, TX, USA).
Results
Of 1,016 patients with ULMCA lesions, 463 (43.4%) were 
in the group guided by IVUS, and 553 (54.4%) were in the 
group guided by angiography. In the IVUS-guided group, 
IVUS-defined optimal results were initially achieved in 
232 patients (50.0%). Of 231 patients who initially attained 
suboptimal results, post-dilation was performed in 105 who 
were therefore included in the IVUS-guided group; the 
remaining 126 patients who did not receive post-dilation 
were included in the angiography-guided group. Thus, there 
were 337 patients (33.2%) in the IVUS-guided group and 679 
(66.8%) in the angiography-guided group who were included 
in the final analysis (Figure 1).
Baseline clinical characteristics
Baseline clinical characteristics are shown in Table 1. Patients 
in the angiography-guided group had a lower  estimated 
glomerular filtration rate (69.2±21.6 mL/min/1.73 m2), 
lower left ventricular ejection fraction (56.7%±11.7%), and 
more frequent ST-segment elevation myocardial infarc-
tion (11.5%) when compared with the IVUS-guided group 
(73.3±22.3 mL/min/1.73 m2, P=0.005; 58.7%±10.1%, 
P=0.011; and 7.1%, P=0.029, respectively).
lesions and procedural characteristics
Table 2 shows that patients in the angiography-guided group 
had more frequent downstream lesions in the left circumflex 
and right coronary artery, and more chronic total occlu-
sion lesions, with more multivessel disease (57.9%) when 
compared with the IVUS-guided group (48.4%, P=0.004). 
As a result, the angiography-guided group had a higher risk 
score stratified by either the Synergy between Percutaneous 
Coronary Intervention with Taxus and Cardiac Surgery score 
or New Risk Stratification method.
As reflected by the difference in lesion complexity 
between the two groups, the transradial approach was used 
less frequently in the angiography-guided group (50.2%) 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
17
6.
8 
on
 2
3-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1302
gao et al
Table 1 Baseline clinical characteristics of the iVUs-guided and angiography-guided groups
IVUS-guided 
(n=337)
Angiography-guided 
(n=679)
P-value
Age, years 66.0±10.4 67.1±10.0 0.098
Males, n (%) 274 (81.3) 526 (77.5) 0.159
BMi, kg/m2 24.0±3.2 24.3±3.2 0.306
hypertension, n (%) 244 (72.4) 489 (72.0) 0.897
hyperlipidemia, n (%) 228 (67.7) 487 (71.7) 0.181
Diabetes, n (%) 109 (32.3) 232 (34.2) 0.562
stroke, n (%) 14 (4.2) 26 (3.8) 0.802
current smoker, n (%) 111 (33.1) 230 (34.1) 0.754
Chronic renal insufficiency, n (%) 88 (26.6) 214 (32.3) 0.066
egFr, ml/min/1.73 m2 73.3±22.3 69.2±21.6 0.005
serum creatinine, µmol/l
Previous Mi, n (%) 
84.3±24.5
60 (17.9)
90.4±41.9
123 (18.1)
0.004
0.920
Acute Mi, n (%) 44 (13.1) 104 (15.3) 0.336
sTeMi 24 (7.1) 78 (11.5) 0.029
nsTeMi 20 (5.9) 26 (3.8) 0.129
cardiac shock 5 (1.5) 15 (2.2) 0.431
chF, n (%) 58 (17.2) 144 (21.2) 0.133
lVeF, % 58.7±10.1 56.7±11.7 0.011
Previous Pci, n (%) 60 (17.8) 119 (17.5) 0.913
Previous cABg, n (%) 2 (0.6) 15 (2.2) 0.069
PAD, n (%) 26 (7.7) 58 (8.5) 0.652
Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; IVUS, intravascular ultrasound; MI, myocardial 
infarction; sTeMi, sT-segment elevation myocardial infarction; nsTeMi, non-sTeMi; chF, congestive heart failure; lVeF, left ventricular ejection fraction; Pci, percutaneous 
coronary intervention; PAD, peripheral artery disease.
Figure 1 Study flow chart.
Abbreviations: iVUs, intravascular ultrasound; UlMcA, unprotected left main coronary artery.
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than in the IVUS-guided group (62.9%, P0.001). Nota-
bly, a larger stent (3.5±0.4 mm) and noncompliant bal-
loon (3.8±0.5 mm) for post-dilation were required in the 
IVUS-guided group, significantly different to those in the 
angiography-guided group (3.4±0.4 mm and 3.6±0.4 mm, 
P=0.001 and P0.001, respectively, Table 3). Finally, there 
were lower rates of complete revascularization (58.3%) and 
angiographic success (93.5%) in the angiography-guided 
group when compared with 74.8% (P0.001) and 99.7% 
(P0.001) in the IVUS-guided group, respectively. 
Unadjusted clinical outcomes
Clinical follow-up was available in approximately 99% of 
patients. Angiographic follow-up was conducted in 79.5% 
of patients in the IVUS-guided group and in 70.7% of 
those in the angiography-guided group. Unadjusted clinical 
 outcomes are summarized in Table 4. At one-year follow-up, 
the incidence of cardiac death, myocardial infarction, and 
TVR in the IVUS-guided group was 1.8%, 11.3%, and 
3.3%, respectively, which was significantly less than the 
6.2% (P=0.002), 17.2% (P=0.013), and 11.8% (P0.001) 
in the angiography-guided group, resulting in less frequent 
composite MACE in the IVUS-guided group (14.8% versus 
27.7%, P0.001). The occurrence of stent thrombosis was 
2.7% in the angiography-guided group, and higher than in 
the IVUS-guided group (0.6%, P=0.026). 
Propensity score matching
The propensity score was calculated, and indicated good 
predictive value (C-statistic 0.78) and calibration char-
acteristics (Hosmer–Lemeshow statistic 9.64, P=0.29). 
After propensity score matching, 291 pairs of patients were 
Table 2 lesion characteristics of the iVUs-guided and angiography-guided groups
IVUS-guided (n=337) Angiography-guided (n=679) P-value
right dominant, n (%) 318 (94.4) 644 (94.8) 0.746
Downstream lesion, n (%)
lesion number, n, (%) 1.2±1.0 1.3±1.0 0.552
lAD 224 (66.5) 479 (70.5) 0.185
lcX 125 (37.1) 324 (47.7) 0.001
rcA 146 (43.3) 369 (54.3) 0.001
Multivessel disease 163 (48.4) 393 (57.9) 0.004
cTO lesion 55 (16.3) 216 (31.8) 0.001
lAD 27 (8.0) 114 (16.8) 0.001
lcX 12 (3.6) 57 (8.4) 0.004
rcA 22 (6.5) 97 (14.3) 0.001
1 cTO 7 (2.1) 45 (6.6) 0.002
Lesions in LM, n (%)
With ostial disease 32 (9.5) 59 (8.7) 0.672
With body disease 16 (4.7) 30 (4.4) 0.812
With whole trunk 60 (17.8) 147 (21.6) 0.152
isolated bifurcation 191 (56.7) 359 (52.9) 0.252
LM bifurcation lesions by Medina classification, n (%) 
0, 0, 1 4 (1.2) 15 (2.2) 0.257
0, 1, 0 39 (11.6) 78 (11.5) 0.968
0, 1, 1 41 (12.2) 63 (9.3) 0.153
1, 0, 0 14 (4.2) 22 (3.2) 0.458
1, 0, 1 15 (4.5) 25 (3.7) 0.553
1, 1, 0 37 (11.0) 77 (11.3) 0.864
1, 1, 1 140 (41.5) 313 (46.1) 0.169
Lesions characteristics in LM
Calcification 109 (32.3) 253 (37.3) 0.123
needing rotablation 9 (2.7) 16 (2.4) 0.761
restenotic 9 (2.7) 17 (2.5) 0.874
Thrombus-containing 7 (2.1) 16 (2.4) 0.778
cTO 3 (0.9) 7 (1.0) 0.831
TiMi grade 0–2 3 (0.9) 11 (1.6) 0.347
ners score, points 23.7±12.6 27.2±13.8 0.001
sYnTAX score, points 28.4±13.8 34.0±15.9 0.001
Abbreviations: IVUS, intravascular ultrasound; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; LM, left main stem; CTO, 
chronic total occlusion; TIMI, Thrombolysis in Myocardial Infarction; NERS, NEw Risk Stratification; SYNTAX, SYNergy between percutaneous coronary intervention with 
TAXus and cardiac surgery.
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Table 4 clinical outcomes in the iVUs-guided and angiography-guided groups
IVUS-guided (n=337) Angiography-guided (n=679) P-value
In-hospital, n (%)
cardiac death 1 (0.3) 16 (2.4) 0.016
Mi 36 (10.7) 105 (15.5) 0.038
sTeMi 2 (0.6) 15 (2.2) 0.059
nsTeMi 34 (10.1) 90 (13.3) 0.147
Tlr 0 7 (1.0) 0.142
cABg 0 0
TVr 1 (0.3) 13 (1.9) 0.072
MAce 37 (11.0) 115 (16.9) 0.012
stent thrombosis 0 8 (1.2) 0.104
Definite 0 5 (0.7) 0.270
Probable 0 3 (0.4) 0.543
At one year, n (%) 
cardiac death 6 (1.8) 42 (6.2) 0.002
Mi 38 (11.3) 117 (17.2) 0.013
sTeMi 4 (1.2) 23 (3.4) 0.040
nsTeMi 34 (10.1) 96 (14.1) 0.069
Tlr 8 (2.4) 64 (9.4) 0.001
cABg 1 (0.3) 6 (0.9) 0.508
TVr 11 (3.3) 80 (11.8) 0.001
MAce 50 (14.8) 188 (27.7) 0.001
stent thrombosis 2 (0.6) 18 (2.7) 0.026
Definite 0 9 (1.3) 0.077
Probable 0 6 (0.9) 0.195
late 2 (0.6) 7 (1.0) 0.730
Abbreviations: iVUs, intravascular ultrasound; Mi, myocardial infarction; sTeMi, sT segment elevation myocardial infarction; nsTeMi, non-sT segment elevation myocardial 
infarction; Tlr, target lesion revascularization; cABg, coronary artery bypass grafting; TVr, target vessel revascularization; MAce, major adverse cardiac events.
Table 3 Procedural characteristics of the iVUs-guided and angiography-guided groups
IVUS-guided (n=337) Angiography-guided (n=679) P-value
Transradial, n (%) 212 (62.9) 341 (50.2) 0.001
Urgent procedures, n (%) 19 (5.6) 56 (8.2) 0.134
Temporary pacing, n (%) 3 (0.9) 12 (1.8) 0.275
iABP, n (%) 20 (5.9) 57 (8.4) 0.163
iib/iiia inhibitor used, n (%) 22 (6.5) 54 (8.0) 0.416
Predilation, n (%) 145 (43.0) 371 (54.6) 0.001
Stent in LM
sirolimus-eluting stent, n (%) 296 (87.8) 583 (86.0) 0.120
stent number, n 1.5±0.6 1.4±0.6 0.377
Diameter, mm 3.5±0.4 3.4±0.4 0.001
length, mm 35.4±18.0 33.3±16.2 0.063
Two-stent techniques for lM bifurcation 154 (45.7) 280 (41.2) 0.176
DK crush 70 (45.5) 110 (39.3) 0.212
crush (classic crush, Mini-crush, reverse crush) 11 (7.1) 23 (8.2) 0.691
culotte 53 (34.4) 72 (25.7) 0.055
T stenting 13 (8.4) 56 (20.0) 0.002
V/sKs stenting 7 (4.5) 19 (6.8) 0.347
Post-dilation 321 (98.2) 543 (98.2) 1.0
Maximum balloon diameter, mm 3.8±0.5 3.6±0.5 0.001
ratio of balloon and stent diameter 1.1±0.1 1.1±0.1 0.033
Maximum pressure, atm 16.5±3.8 16.2±4.0 0.387
complete revascularization, n (%) 252 (74.8) 396 (58.3) 0.001
Final TiMi grade 3, n (%) 337 (100) 676 (99.6) 0.555
Angiographic success 336 (99.7) 635 (93.5) 0.001
Abbreviations: iABP, intra-aortic balloon pump; iVUs, intravascular ultrasound; lM, left main stem; DK, double kissing; sKs, simultaneous kissing stents; TiMi, Thrombolysis 
in Myocardial infarction.
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matched (Supplementary material, Table S1), and there 
was a significant difference in composite MACE between 
the IVUS-guided group (16.2%) and the angiography- 
guided group (24.4%, P=0.013, Table 5, Figure 2), mainly 
driven by increased cardiac death (5.2% versus 1.7%, 
P=0.023) and TVR (10.0% versus 3.4%, P=0.014) in the lat-
ter group. By Cox regression multivariable analysis, the only 
independent predictor of MACE was IVUS guidance (hazard 
ratio 0.66, 95% confidence interval 0.46–0.96, P=0.024).
Discussion
The major finding of this study was that IVUS-guided 
stenting for ULMCA lesions was associated with dramatic 
reductions in both the unadjusted and adjusted one-year rate 
of composite MACE, mainly due to a significant reduction 
of cardiac death and TVR.
ULMCA stenosis is characterized by frequent distal 
bifurcation involvement, larger parent and daughter vessel 
diameters, and wider distal bifurcation angle.2,3,12 It is still 
unclear whether clinical outcomes of ULMCA intervention 
using DES could be improved by IVUS guidance. A meta-
analysis by Zhang et al demonstrated that the IVUS-guided 
DES implantation is associated with significant reductions 
Table 5 clinical outcomes after propensity score matching
IVUS-guided (n=291) Angiography-guided (n=291) P-value
In-hospital, n (%)
cardiac death 1 (0.3) 3 (1.0) 0.616
Mi 35 (12.0) 39 (13.4) 0.619
sTeMi 2 (0.7) 5 (1.7) 0.447
nsTeMi 33 (11.3) 34 (11.7) 0.897
Tlr 0 2 (0.7) 0.479
cABg 0 0
TVr 1 (0.3) 3 (1.0) 0.616
MAce 36 (12.4) 41 (14.1) 0.541
stent thrombosis 0 3 (1.0) 0.247
Definite 0 2 (0.7) 0.479
Probable 0 1 (0.3) 1.000
At one year, n (%)
cardiac death 5 (1.7) 15 (5.2) 0.023
Mi 36 (12.4) 44 (15.1) 0.336
sTeMi 3 (1.0) 10 (3.4) 0.050
nsTeMi 33 (11.3) 35 (12.0) 0.796
Tlr 8 (2.7) 24 (8.2) 0.004
cABg 1 (0.3) 1 (0.3) 1.000
TVr 10 (3.4) 29 (10.0) 0.002
MAce 47 (16.2) 71 (24.4) 0.014
stent thrombosis 1 (0.3) 7 (2.4) 0.075
Definite 0 2 (0.7) 0.479
Probable 0 3 (1.0) 0.247
late 1 (0.3) 2 (0.7) 1.000
Abbreviations: iVUs, intravascular ultrasound; Mi, myocardial infarction; sTeMi, sT-segment elevation myocardial infarction; nsTeMi, non-sT segment elevation myocardial 
infarction; Tlr, target lesion revascularization; cABg, coronary artery bypass grafting; TVr, target vessel revascularization; MAce, major adverse cardiac events.
in death, MACE, and stent thrombosis when compared with 
angiographic guidance.11 Also, data from the Efficacy of 
Xience/promus versus Cypher in rEducing Late Loss after 
stENTing (EXCELLENT) trial (ClinicalTrials.gov identifier 
NCT00698607) showed that IVUS-guided stenting for non-
left main lesions had higher release of periprocedural myo-
cardial biomarkers, reflecting the more aggressive procedures 
performed with IVUS guidance.20 Furthermore, a subgroup 
analysis from the MAIN-COMPARE (Revascularization for 
Unprotected Left Main Coronary Artery Stenosis: Compari-
son of Percutaneous Coronary Angioplasty Versus Surgical 
Revascularization) study showed that 3-year mortality was 
significantly lower in the IVUS-guided group than in the 
angiography-guided group.12 It should be noted that the risks 
of myocardial infarction and TVR were not influenced by 
IVUS guidance in that study. Overall, the current data regard-
ing the importance of IVUS-guided stenting of ULMCA 
lesions is insufficient to provide clinical advantages.
In our study, patients in the angiography-guided group 
had more frequent comorbidities and more complex lesions, 
ie, more downstream lesions, chronic total occlusion lesions, 
ST-segment elevation myocardial infarction, renal insuffi-
ciency/impairment, left ventricular dysfunction, and higher 
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risk scores.16,17,21 These factors, which make this subset of 
patients more high risk, may have influenced the primary 
operators against the use of IVUS. The unadjusted difference 
in either composite MACE or individual endpoints between 
these two groups may be undermined by the discrepancies 
in baseline characteristics of the angiography-guided group. 
Nevertheless, after propensity score matching, the difference 
in composite MACE between the two groups was sustained 
and the results were still favorable towards the use of IVUS 
guidance. Notably, the wider unadjusted range of myocardial 
infarction between these two groups became narrower after 
propensity score matching; cardiac death and TVR were still 
commonly seen in the angiography-guided group. Possible 
reasons for the favorable results using IVUS guidance include 
its more accurate quantification of stent diameter, less late 
loss, and fewer requirements for revascularization. Moreover, 
the stent thrombosis rate in the angiography-guided group 
was eight times higher when compared with the IVUS-guided 
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Figure 2 Freedom from cardiac events in intravascular ultrasound guidance versus angiography guidance in the propensity score-matched population. Freedom from cardiac 
death (cD) (A), myocardial infarction (Mi) (B), target lesion revascularization (Tlr) (C), target vessel revascularization (TVr) (D), major adverse cardiac events (MAce) 
(E), and stent thrombosis (sT) (F) after intravascular ultrasound guidance (red line) versus angiography guidance (blue line) at one-year follow-up in the propensity score-
matched population.
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group, implying that the difference in stent thrombosis rate 
would be significant if the sample size was expanded further, 
a postulation confirmed by our previous study of patients 
with coronary bifurcation lesions.9 All these results strongly 
support IVUS guidance as being the only independent factor 
of MACE by multivariate analysis. 
Park et al12 reported significant reduction of mortality 
when guided by IVUS in the MAIN-COMPARE study; this 
was in line with our data. In contrast with our findings, they 
did not identify a decrease in the rate of TVR in the IVUS-
guided group. This difference might be due to the different 
definitions of IVUS guidance used in these two studies. In 
the MAIN-COMPARE registry, the procedure was consid-
ered IVUS-guided when IVUS assessment was performed 
to evaluate stenting status, a definition that included patients 
with suboptimal results but without further interventions. In 
contrast, patients in our study were considered angiography-
guided if further intervention was not performed after IVUS 
assessment. We believe our definition of IVUS-guided DES 
implantation reflected the real grouping of IVUS guidance 
versus non-IVUS guidance. Furthermore, the differences 
in techniques and types of DES used as well as duration of 
follow-up may be other factors contributing to the discrep-
ancy in clinical results between these studies, despite the 
fact that both demonstrated an overall significant reduction 
in mortality by IVUS guidance. 
study limitations
The current study has several limitations. It is underpowered 
because it was an open-label, nonrandomized registry con-
sisting of a small cohort of patients. Use of a larger patient 
population and propensity score matching would overcome 
these problems. Second, quantitative IVUS and angiographic 
analysis were not performed. Third long-term follow-up 
after DES implantation was not done. Extended follow-up 
may be critical to assess the long-term clinical benefit of 
IVUS-guided ULMCA stenting. Finally, although the distal 
segment of the left main is commonly involved, we did not 
perform a subgroup analysis to elucidate the importance of 
IVUS guidance for distal left main lesions in this cohort of 
all left main lesions.
Conclusion 
Our registry demonstrates that, after propensity score match-
ing, IVUS-guided ULMCA stenting was associated with 
reduced one-year MACE compared with angiography-guided 
stenting, mainly driven by a decrease in cardiac death and 
TVR. However, a randomized study with a larger patient 
sample size is needed to further address the real advantages 
of IVUS over angiography guidance in this patient and 
lesion subset.
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Table S1 Baseline clinical, angiographic, and procedural characteristics after propensity matching
IVUS-guided (n=291) Angiography-guided (n=291) P-value
Clinical variables
egFr, ml/min/1.73 m2 72.2±21.0 69.8±20.1 0.160
serum creatinine, µmol/l 83.1±25.6 87.3±30.0 0.070
sTeMi 26 (8.9) 28 (9.6) 0.775
lVeF, % 57.3±10.2 56.9±8.2 0.602
Angiographic variables
Downstream lesion, n (%)
lcX 107 (36.8) 117 (40.2) 0.394
rcA 141 (48.5) 152 (52.2) 0.362
Multivessel disease 143 (49.1) 155 (53.2) 0.320
cTO lesion 59 (20.3) 73 (25.1) 0.166
lAD 28 (9.6) 39 (13.4) 0.153
lcX 19 (6.5) 23 (7.9) 0.522
rcA 21 (7.2) 30 (10.3) 0.187
1 cTO 11 (3.8) 17 (5.8) 0.245
ners score, points 26.7±11.9 28.1±14.3 0.200
sYnTAX score, points 30.1±16.2 32.0±13.8 0.128
Procedural variables
Transradial, n (%) 166 (57.0) 157 (53.9) 0.453
Predilation, n (%) 143 (49.1) 152 (52.2) 0.456
stent diameter in lM, mm 3.5±0.4 3.4±0.8 0.057
T stenting techniques for lM bifurcation 36 (12.3) 51 (17.5) 0.081
Maximum balloon diameter, mm 3.7±0.1 3.6±0.9 0.060
ratio of balloon and stent diameter 1.1±0.6 1.1±0.2 1.000
complete revascularization, n (%) 185 (63.6) 175 (60.1) 0.557
Angiographic success 283 (97.3) 281 (96.6) 0.632
Abbreviations: eGFR, estimated glomerular filtration rate; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; LAD, left anterior 
descending artery; LCX, left circumflex artery; RCA, right coronary artery; LM, left main; CTO, chronic total occlusion; TIMI, Thrombolysis in Myocardial Infarction; NERS, 
NEw Risk Stratification; SYNTAX, SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery.
Supplementary material
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
17
6.
8 
on
 2
3-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
